Argos Therapeutics, Inc. announced consolidated earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company’s net loss was $12.246 million, or $0.32 per basic and diluted share, compared to a net loss of $20.078 million, or $0.97 per basic and diluted share, for the same period in 2015. Revenue for the three months ended September 30, 2016 totaled $0.146 million compared to $0.158 million for the same period in 2015. Operating loss was $12.203 million against $19.758 million a year ago. For the nine months, the company’s net loss was $37.673 million, or $1.30 per basic and diluted share, compared to a net loss of $57.229 million, or $2.81 per basic and diluted share, for the same period in 2015. Revenue for the nine months ended September 30, 2016 totaled $0.781 million compared to $0.444 million for the same period in 2015. Operating loss was $36.599 million against $55.604 million a year ago.